Zacks Investment Research upgraded shares of ESSA Pharma Inc. (NASDAQ:EPIX) (TSE:EPI) from a hold rating to a buy rating in a research note published on Monday. The firm currently has $0.50 price objective on the stock.
According to Zacks, “ESSA Pharma Inc. is a pharmaceutical company. The company focused on the development of small molecule drugs for the treatment of cancer, with focus on advanced prostate cancer. ESSA Pharma Inc. is based in Vancouver, Canada. “
Several other research analysts have also weighed in on the company. Dawson James reissued a buy rating on shares of ESSA Pharma in a research report on Thursday, August 3rd. ValuEngine lowered ESSA Pharma from a sell rating to a strong sell rating in a research report on Wednesday, June 7th. Finally, Bloom Burton reissued a buy rating on shares of ESSA Pharma in a research report on Thursday, May 18th. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company’s stock. The stock currently has an average rating of Hold and a consensus target price of $4.75.
ESSA Pharma (EPIX) traded down 0.21% during midday trading on Monday, reaching $0.29. The company had a trading volume of 101,824 shares. The company’s market capitalization is $8.44 million. The stock has a 50-day moving average price of $0.30 and a 200 day moving average price of $1.38. ESSA Pharma has a 12-month low of $0.26 and a 12-month high of $2.80.
ESSA Pharma Company Profile
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses on the development of novel and proprietary therapies for the treatment of prostate cancer. Its product candidate is EPI-506, an oral small molecule pro-drug that is in Phase 1/2 clinical trial, which blocks the N-terminal domain of the androgen receptor.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ESSA Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma Inc. and related companies with our FREE daily email newsletter.